Recent research has identified abnormal SCFA concentrations in AD patients, with SCFAs postulated to exert anti-inflammatory effects, inhibit tau protein aggregation, and contribute to the maintenance of blood–brain barrier integrity [34]. The gene discussed is MAPT; the disease is Alzheimer disease.